Institutional members access full text with Ovid®

Share this article on:

Cranial Neuralgias

Cheshire, William P. Jr MD, FAAN

CONTINUUM: Lifelong Learning in Neurology: August 2015 - Volume 21 - Issue 4, Headache - p 1072–1085
doi: 10.1212/CON.0000000000000194
Review Articles

Purpose of Review: Pain arising from cranial neuralgias represents a significant health burden. Successful treatment depends on accurate diagnosis, which requires knowledge of neuroanatomy and pathophysiology as well as familiarity with the varied clinical presentations encountered in neurologic practice. This article delineates the relevant anatomy, clinical features, and management of the most common primary and secondary cranial neuralgias.

Recent Findings: Trigeminal neuralgia, which can result from neurovascular compression or demyelination, is a particularly severe form of facial pain. Herpes zoster virus is a common cause of neuralgia that causes herpes zoster ophthalmicus acutely and postherpetic neuralgia chronically. Rarer facial pain syndromes arising from a single nerve include glossopharyngeal neuralgia, nervus intermedius neuralgia, and paratrigeminal oculosympathetic syndrome.

Summary: In patients presenting with a cranial neuralgia, unless the etiology is apparent (eg, herpes zoster), cranial imaging studies should be undertaken to look for structural abnormalities such as neoplasm, granulomatous disease, demyelinating disease, or vascular malformations. Management of both common and rare cranial neuralgias is often challenging and is best guided by the most recent available evidence.

Address correspondence to Dr William P. Cheshire Jr, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, cheshire@mayo.edu.

Relationship Disclosure: Dr Cheshire has received personal compensation for manuscript preparation from Turner White Communications, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Cheshire discusses the unlabeled/investigational use of oxcarbazepine, baclofen, phenytoin, fosphenytoin, gabapentin, botulinum toxin, tizanidine, pimozide, and motor cortex stimulation for the treatment of trigeminal neuralgia; tricyclics, pregabalin, opioids, tramadol, and capsaicin for the treatment of postherpetic neuralgia; carbamazepine, gabapentin, lamotrigine, and tricyclics for the treatment of nervus intermedius neuralgia; and nonsteroidal anti-inflammatory drugs, muscle relaxants, tricyclics, gabapentin, and occipital nerve stimulators for the treatment of occipital neuralgia.

© 2015 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website